Amgen Reclaims Rights From GSK To Grow In Ex-US Markets
This article was originally published in Scrip
Executive Summary
Amgen Inc. will reacquire ex-US rights to its cancer drug Vectibix (panitumumab) and bone drugs Prolia (denosumab) and Xgeva (denosumab) in 48 countries from GlaxoSmithKline PLC, which generated $111m in combined revenue from the products in 2014.
You may also be interested in...
Amgen-Dr Reddy's Build On India Alliance
Amgen is building on its alliance with Dr. Reddy’s Laboratories in India, shifting out certain products previously sold by GlaxoSmithKline in the country to the Hyderabad-based firm.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.